Incretin Atlas › Trials › SURMOUNT-MMO
SURMOUNT-MMO
Tirzepatide · Obesity, morbidity and mortality
Design
- Molecule(s)
- Tirzepatide
- Population
- Obesity, morbidity and mortality
- Official title
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- active not recruiting · 2022-10 → 2027-10
- Participants
- 15374
- Registry
- NCT05556512
Ongoing outcome trial
| Trial | Molecule | Population | Primary endpoint | n | Registry status | Primary completion | Registry |
|---|---|---|---|---|---|---|---|
| SURMOUNT-MMO | Tirzepatide | Obesity, morbidity and mortality Obesity without diabetes (T2D excluded), established CVD or risk factors | Composite of death and CV events | 15374 | active not recruiting | 2027-10 | NCT05556512 |
No results yet; the primary completion date comes from the registry.
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: SURMOUNT-MMO. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/surmount-mmo/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.